skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Nimotuzumab (Code C2733)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Nimotuzumab

Definition: A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.

NCI-GLOSS Definition: A monoclonal antibody being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Nimotuzumab binds the epidermal growth factor receptor (EGFR) and blocks cancer cells that depend on epidermal growth factor for growth.

Display Name: Nimotuzumab

Label: Nimotuzumab

NCI Thesaurus Code: C2733 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1570482  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
TheraCim hR3

External Source Codes: 
CAS Registry Number 828933-51-3 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 507582
PDQ Open Trial Search ID 507582 (check for NCI PDQ open clinical trial info)
UMLS CUI C1570482

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Glioma
code C2733
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name TheraCim_hR3
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom